Authors
Latest:
Creating a Digital Solution Patients and HCPs Will UseDeveloping a digital health solution that patients and HCPs will use requires creating technology that addresses unmet needs, integrates with clinical care pathways, and has strong user safeguards, writes Matt Norton.
Latest:
Why Are We Surrendering to COVID?Industry must continue research and development to combat the pandemic.
Latest:
Marketers: Physicians are People FirstUnderstanding the changes in day-to-day life for physicians during COVID and how life science executives can address them.
Latest:
Unlocking Oncology Insights - Innovations in Evidence Generation With RWE SolutionsThe rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.
Latest:
Omnichannel Marketing Challenges for European Life Sciences Companies: A Data Science PerspectiveAs EU brand leaders build their omnichannel customer engagement strategies, they need to address challenges in the European environment with a well-thought-out deployment plan.
Latest:
Don’t Waste A Crisis: How Paratek is Navigating the Business Implications of the COVID-19 PandemicA look at how pharmaceutical company, Paratek is navigating the launch of a new antibiotic during the COVID-19 pandemic.
Latest:
Biotech’s Survival Story: Companies Bear Down for Lean YearsWhile large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong.
Latest:
Redefine the Digital Experience for Life Science InnovationTuesday, June 29, 2021 at 2pm EDT | 1pm CDT | 11am PDT
Latest:
How Should Biotechs Strategize for 2025Strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.
Latest:
China 2021: The NRDL ReadoutChina‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.
Latest:
It’s Time for a Fresh Approach to Patient Data in Rare DiseaseCurrent practices leave much to be desired with increasing commercial needs.
Latest:
New Product Planning: The Function's Evolution in PharmaWith an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.
Latest:
The C-Suite’s Frontline Workers in Digital ChangeHow the CIO role has transformed and strengthened against the backdrop of COVID-19.
Latest:
The Agile Future of Medical Information: Meeting 21st-Century Demands for HealthcareCOVID-19 pandemic has accelerated raised expectations for medical information professionals.
Latest:
At the Heart of Pharma: ESG has Arrived as a Central StrategyPharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.
Latest:
Is Your Demand Side Platform (DSP) Ready for the Cookieless Future?A cookieless future is on the horizon, so marketers across all industries are being forced to rethink their strategies and plan for the future. What does that entail?
Latest:
Realizing the NHS’s Digital PotentialWesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.
Latest:
5 Challenges of Increasing Online Scientific DiscussionWednesday November 9, 2022, 11am EDT | 8am PDT Discover insights and find ways to engage in the 24/7 world of online digital scientific exchange. Learn to listen to digital opinion leaders and find opportunities to engage.
Latest:
Four Critical Considerations for Launching Digital Diagnostic ToolsCreating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Latest:
Cleared and Graded: Modernizing the 510(k) PathwayDue to increasing complexity of modern technology, FDA should consider updating its 510(k) process.
Latest:
Navigating PV Divergence: Compliance Tips for New EntrantsWith small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.
Latest:
COVID-19: Is the Vaccine Race Over?Cliodhna McDonough and Emily Lockey give a UK perspective on the potential pros and cons of the three leading candidates in the COVID-19 vaccine race.
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Commercial Models for the Changing Life Sciences MarketLife sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
Latest:
Commercializing Cannabis and Patent LitigationHow the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.
Latest:
Patient Treatment & Travel: The Need for Stepped-Up SupportDesigning an effective travel and lodging patient hub program in pharma.
